In a recent interview, Sarah Friedewald, MD, discussed new study findings for an adjunctive AI software for digital breast tomosynthesis (DBT) that revealed nearly equivalent sensitivity and specificity rates for breast cancer across a diverse cohort.
One of the key challenges with the development of artificial intelligence (AI) tools in radiology has been a lack of representative diversity in test sets used to assess the performance of AI algorithms. However, new research with an emerging software for digital breast tomosynthesis (DBT) demonstrated nearly equivalent sensitivity for breast cancer detection across different races and ethnicities.
For the study, presented at the Radiological Society of North America (RSNA) conference, researchers evaluated the Genius AI Detection 2.0 software (Hologic) in a review of DBT data for over 7,500 women. The cohort included 5,395 White women, 956 Black women, 774 Hispanic women and 279 Asian women, according to the study.
The researchers found that the AI software offered an overall sensitivity rate of 90.1 percent, including similar sensitivity rates for White (90.3 percent), Black (88.6 percent), Hispanic (90.1 percent) and Asian women (91.5 percent).
“I was really happy to see that the Genius AI (Detection) 2.0 (software) was able to perform similarly in all of the populations studied albeit with a (slightly higher) improvement in cancer detection in the Asian population,” noted lead study author Sarah Friedewald, M.D., the vice chair for women’s imaging and chief of breast imaging in the Department of Radiology at the Northwestern Medicine Feinberg School of Medicine.
(Editor’s note: For additional coverage of RSNA, click here.)
In a recent interview, Dr. Friedewald shared her perspective on the study findings and the potential of AI in effectively triaging patients who need supplemental imaging. While she emphasized the need for continued research in real-world settings, Dr. Friedewald said AI can play a key role in mitigating disparities in breast cancer detection and care.
“As long as we are cognizant of our test sets and that we continually monitor the performance of the artificial intelligence, we will be confident that we are serving our patients equally and that everybody will benefit from the technology,” emphasized Dr. Friedewald.
(Editor’s note: For related content, see “Mammography Study: Paying for Adjunctive AI Screening Led to 43 Percent Higher Rate of Breast Cancer Detection,” “FDA Clears Updated AI Platform for Digital Breast Tomosynthesis” and “AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer.”)
For more insights from Dr. Friedewald, watch the video below.
Reference
1. Friedewald SM, Kshirsagar A, Smith AP, Pohlman S. Performance of a digital breast tomosynthesis AI detection algorithm in common US racial/ethnic groups. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.